Sutro Biopharma Inc (NASDAQ:STRO) currently has a daily average trading volume of 1.43M but it saw 1407425 shares traded in last market. With a market cap of 47.92M USD, the company’s current market price of $0.57 came falling about -8.90 while comparing to the previous closing price of $0.63. In past 52 weeks, the stock remained buoying in the range of price level as high as $5.17 and as low as $0.54. In the recent trading on the day, stock has struck highest price mark of $0.57 while lowest mark touched by it was $0.6018.
Taking a look at 20-day trading activity of Sutro Biopharma Inc (STRO) gives us an average price of $0.7175, while its current price level is -88.94% below from 52-week high level whereas it is 5.91% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $1.2932 while that of 200 days or SMA-200 reads an average of $2.7871. A closer look into the stock’s movement over the week reveals that its volatility is standing at 21.85% during that period while stretching the period over a month that decreases to 14.85%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 30.96 which implies that the stock is in neutral territory.
Wedbush downgraded its recommendation for the stock as a “Neutral” from “Outperform” on March 14, 2025 while assigning a price target range of $8-$2.
Over the week, STRO’s stock price is moving -3.46% down while it is -57.31% when we observe its performance for the past one month. Year-to-date it is -68.91% down and over the past year, the stock is showing a downside performance of -86.97%.
The company is expected to be releasing its next quarterly report on 2025-Mar-12, for which analysts forecasted an EPS of 0 while estimate for next year EPS is -2.48. In next quarter, company is expected to be making quarterly sales of $11.54M as analysts are expecting the sales for current fiscal year at $47.14M and seeing the company making $51.77M in sales next year. Moreover, analysts are in estimates of $11.61M for current-quarter revenue.
Currently, Sutro Biopharma Inc’s total number of outstanding shares is 82.53M with 4.10% of that held by the insiders while 73.94% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -94.35% and return on equity (ROE) at -234.19%. Stock’s beta reads 1.86. Stock has a price to book (P/B) ratio of 1.06 while price to sale or P/S ratio amounts to 0.77. Its return on asset (ROA) is -53.02% on average.
